Post-Market Surveillance Obligations in Nigeria: The Four Statutory Actions of Article 12

1. Key takeaways

Nigeria’s post-market surveillance obligations are set out in Article 12, in four paragraphs, with a very clear allocation of responsibility:

• Article 12(1): the manufacturer must perform a pre-market evaluation and submit the report together with the application;
• Article 12(2): the manufacturer must establish a post-market surveillance (PMS) system which, at a minimum, can monitor, collect, evaluate and react;
• Article 12(3): manufacturers and importers must comply with the relevant pharmacovigilance provisions;
• Article 12(4): importers, distributors and authorised representatives must report user feedback to both the manufacturer and NAFDAC.

Four verbs — monitor, collect, evaluate, react — constitute Nigeria’s statutory minimum configuration for a PMS system. Anything less than all four is not a compliant system, whatever the internal quality manual claims.

2. Legal basis

3. Expert insights

Insight one: the pre-market evaluation report under Article 12(1) is part of the application dossier, not a post-market action.

Many companies understand PMS as something that begins after the certificate is granted. But Article 12(1) expressly requires the manufacturer to perform a pre-market evaluation and submit the report together with the application. In other words, PMS in Nigeria starts at the application stage — you must file a pre-market evaluation report when you apply. Treating this report as a compliance afterthought means the dossier is incomplete on day one, and gaps found during screening delay the whole registration timeline.

Insight two: monitor, collect, evaluate, react are four mechanisms, not four adjectives.

Article 12(2) defines the minimum capability of a PMS system as four actions. In practice these correspond to four different mechanisms: monitoring (proactive signal detection, such as complaint trending and literature searching), collection (channel building, such as hospital feedback and distributor reporting), evaluation (causality assessment and risk analysis), and reaction (corrective actions, recalls, labelling revisions). A system that only collects, without evaluating and reacting, does not constitute a compliant PMS system. Auditors will ask to see the output of each verb, not the existence of a mailbox.

Insight three: Article 12(3) anchors device vigilance to pharmacovigilance provisions — a distinctly Nigerian feature.

Article 12(3) requires manufacturers and importers to comply with the pharmacovigilance provisions. This means that device vigilance obligations in Nigeria are not a purely device-specific standalone regime but share a normative framework with the pharmacovigilance system. A system built under Articles 83–86 of the EU MDR or under the Chinese measures on adverse event monitoring and re-evaluation of medical devices needs a Nigeria mapping exercise, in particular to confirm the submission channels and timelines. The mapping should be a written annex to the quality system, not a mental note, because local staff will follow what is written.

Insight four: the user feedback obligation in Article 12(4) falls on importers, distributors and authorised representatives, and it is two-directional.

Article 12(4): importers, distributors and authorised representatives must report user feedback to the manufacturer and NAFDAC — both recipients. This is the link most easily missed by foreign companies: local partners often assume that reporting to the manufacturer is enough, when in fact there is a separate statutory duty to report to NAFDAC. This provision must be written into distribution agreements and authorised representative agreements, with named responsible persons, agreed timelines and evidence of submission retained for every report.

Insight five: PMS, suspension grounds and recalls are three lines pointing at the same risk.

Article 8(1)(d) (device ineffective for the approved purpose) is a suspension ground; PMS-GDL-020-00 is the operational framework for recalls; Article 12 is the daily obligation. PMS is the outpost, the recall is the remedy, suspension is the consequence — only when the three are linked do they form a complete post-market compliance loop. A quarterly review that reads PMS outputs against suspension grounds and recall criteria turns three disconnected obligations into one managed process.

4. Practical recommendations

1. Prepare the pre-market evaluation report at the application stage and submit it together with the registration application (Article 12(1)).
2. Build the PMS system around the four actions, each supported by its own SOP and record forms.
3. Perform a vigilance system mapping: map existing EU or Chinese vigilance SOPs onto Nigeria’s pharmacovigilance provisions and confirm channels and timelines.
4. Write the two-directional reporting duty of Article 12(4) into distribution and authorised representative agreements, with agreed reporting timelines.
5. Link PMS outputs to risk assessment under Article 8(1)(d), producing a quarterly assessment report.
6. Align the recall contingency plan with PMS-GDL-020-00 (see article 36 for details).

5. Verification checklist

• □ The pre-market evaluation report has been submitted with the application (Article 12(1)).
• □ The PMS system covers the four actions of monitoring, collection, evaluation and reaction (Article 12(2)).
• □ Vigilance reporting channels and timelines are aligned with the official provisions (Article 12(3)).
• □ Distribution and authorised representative agreements contain the two-directional reporting duty to the manufacturer and NAFDAC (Article 12(4)).
• □ Quarterly PMS assessment reports are linked to risk determination under Article 8(1)(d).
• □ The recall contingency plan has been prepared in line with PMS-GDL-020-00.

Regulatory information verified as of 29 October 2026. All citations have been checked against the official NAFDAC Regulations text (S.I. No. 42 of 2024, Articles 8(1)(d), 11, 12(1)–(4), 13) and the two guidelines (PMS-GDL-016-01, effective 27 September 2024; PMS-GDL-020-00, effective 30 September 2024); Part 8 (vigilance) of the 2025 draft was published on 23 July 2025 and is not yet gazetted, and is referenced only as an indication of regulatory direction.

• Local resources in Nigeria: GRZAN can coordinate locally licensed importer and authorised representative resources, covering NAPAMS electronic submission, dossier screening permit coordination, import permits, sample delivery and laboratory analysis support.
• Service capabilities: classification determination, registration pathway selection, technical documentation (IMDRF ToC), CMFS and legalisation, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal.
• Contact: hito.lin@grzan.cn; website www.grzan.cn; email info@grzanglobal.com.